3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
3
Hodgkin Disease
3
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Neoplasms by Site
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia
1
Carcinoma, Renal Cell
1
Bronchiolitis Obliterans Syndrome
1
Interventions
mogamulizumab
4
denileukin diftitox
4
Vorinostat
4
Panobinostat
4
zanolimumab
3
cobomarsen
3
Brentuximab Vedotin
3
Bexarotene
3
tenalisib
2
selinexor
2
marizomib
2
hypericin
2
Vitamin B 12
2
Rituximab
2
Folic Acid
2
A-dmDT390-bisFv(UCHT1) protein
2
10-propargyl-10-deazaaminopterin
2
tislelizumab
1
tinostamustine
1
sapacitabine
1
romidepsin
1
resminostat
1
quisinostat
1
ontuxizumab
1
navitoclax
1
forodesine
1
fludarabine phosphate
1
enzastaurin
1
belinostat
1
abexinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Cutaneous
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts